Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01471574 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 549
- Enrollment target
NCT01471574 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 549 participants.
The verdict
NCT01471574, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 549 participants
- Enrollment target
Study Summary
The purpose of this open label study is to evaluate the safety and efficacy of daclatasvir plus pegylated interferon-alfa 2a and ribavirin in untreated hepatitis C virus in patients coinfected with HIV
Interventions
- DRUG Ribavirin
- DRUG Daclatasvir
- DRUG PEG-Interferon alfa 2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 549 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01471574
The ClinicalTrials.gov registry entry for NCT01471574 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 549 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT01471574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01471574 about?
NCT01471574 is a clinical study titled "Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus". The purpose of this open label study is to evaluate the safety and efficacy of daclatasvir plus pegylated interferon-alfa 2a and ribavirin in untreated hepatitis C virus in patients coinfected with HIV
What is the current status of trial NCT01471574?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 549 participants. The study started on 2011-12. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01471574?
The interventions under investigation include: Ribavirin (DRUG), Daclatasvir (DRUG), PEG-Interferon alfa 2a (DRUG).
Who is sponsoring clinical trial NCT01471574?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.